🖊️ What Actually Counts as a “Smart” Insulin Pen

The category splits into two meaningfully different tiers, and conflating them is where a lot of confusion starts.

Dose-logging pens simply record when and how much insulin you took, without offering a dosing recommendation. The NovoPen 6 and NovoPen Echo Plus from Novo Nordisk are the most widely used connected pens globally in this category — on the pen itself, you see your last dose and the time since you took it, full stop. This is a real, useful feature (missed-dose confusion is a genuine everyday problem), but it’s not decision support.

Dose-recommending systems go further: they pull in real-time glucose data from a connected continuous glucose monitor (CGM) and use it to suggest a specific dose, based on settings a person’s healthcare provider configures in advance. This is a meaningfully bigger claim, and it’s the category that carries real FDA clearance and outcome data worth examining closely.

✅ What’s Actually FDA-Cleared Right Now

InPen (Medtronic)

Originally developed by Companion Medical and acquired by Medtronic, InPen was the first smart insulin pen system cleared by the FDA, in 2016 for ages 12 and up, with an expanded 2020 clearance covering all ages and additional meal-dosing modes. It’s a reusable pen using a prefilled 300-unit cartridge of rapid-acting insulin (cleared for use with Fiasp, Humalog, and NovoLog), delivering bolus doses in 0.5-unit increments up to 30 units per dose. It connects via Bluetooth to the Insights by InPen app, integrates in real time with Medtronic’s Guardian Connect CGM, and can also connect with Dexcom’s G6 sensor.

Bigfoot Unity (Bigfoot Biomedical, now part of Abbott)

Cleared by the FDA in 2021 for ages 12 and up, Bigfoot Unity takes a different hardware approach: rather than being a pen itself, it’s a smart cap system that fits onto standard disposable insulin pens from major manufacturers including Eli Lilly, Novo Nordisk, and Sanofi. It integrates with Abbott’s FreeStyle Libre 2 sensor and displays a recommended dose directly on the cap’s screen, along with current glucose and trend arrows — without requiring separate manual entry. It includes a mandatory real-time alarm when glucose drops to 55 mg/dL or below.

MiniMed Go (Medtronic)

The newest entrant, cleared by the FDA on January 12, 2026. MiniMed Go integrates the InPen smart pen with Abbott’s Instinct CGM sensor in a single app, adding real-time dosing insights, missed-dose alerts, a dose calculator, and CareLink software integration for care teams. Its clearance covers insulin-requiring type 1 and type 2 diabetes for ages 7 and up, with adult supervision required for ages 2 through 6. Medtronic began a gradual European rollout of a related Smart MDI system in February 2026, with U.S. availability of some sensor combinations still pending FDA review as of this writing.

DUKADA Sense

DUKADA Sense is a more flexible, adaptive connected-cap platform that detects both the timing and size of doses on injection pens, transmitting data via Bluetooth to a partner app or digital ecosystem, without necessarily providing an on-device dosing recommendation itself — a useful example of the category’s range between simple logging and full decision support.

🔬 What the Outcome Data Actually Shows

This is one of the few corners of connected health tech where a real peer-reviewed outcome study exists, and it’s worth walking through carefully, including its limits.

A 2025 study published in Diabetic Medicine (Laurenzi et al., DOI: 10.1111/dme.70161) analyzed real-world data from 1,852 people with type 1 diabetes using the Smart MDI system (the InPen paired with a CGM) across 21 countries. The study found a mean Time in Range (TIR) of 55.7% across all users. But it also found a meaningful pattern: users who responded with a bolus dose within one hour to more than 75% of their missed-dose and high-glucose alerts achieved substantially higher TIRs — 67.2% and 71.5% respectively, both closer to the internationally recommended 70% TIR target.

These systems’ real value may lie less in the dosing math itself and more in prompting timely action — the alert is only as useful as a person’s response to it.

⚖️ The Real Trade-Offs Compared to a Pump

Smart pens exist as a category precisely because full insulin pump systems aren’t the right fit for everyone. Compared to a pump, a smart pen system generally means:

• Lower cost and less hardware commitment — no infusion set to wear continuously, no pump to attach to your body
• More manual involvement — you’re still administering each injection yourself; the system supports the decision, not the delivery
• Flexibility for people who prefer injections — for reasons ranging from lifestyle to comfort to insurance coverage, not everyone wants or has access to a pump
• A real dependency on consistent CGM use — the dose-recommending systems above only work as well as the CGM data feeding them, and (per InPen’s connectivity limits) some CGM combinations only provide delayed rather than real-time data in the US, which matters for how quickly a recommendation reflects your actual glucose trend

None of this makes a smart pen inherently better or worse than a pump — it makes it a genuinely different tool for a different set of priorities, which is exactly why this category has grown rather than simply being replaced by pumps.

📊 Quick Comparison

📋 Questions to Ask Before Choosing a Smart Pen System

• Does this system provide dose recommendations, or only log doses? These are very different products solving different problems.
• Which CGM does it require, and do you already use (or have coverage for) that specific sensor? Compatibility is often the real deciding factor, not features.
• Is the manufacturer actively supporting and updating this product? Bigfoot Unity’s reduced visibility since its acquisition by Abbott is a real example of why this is worth asking directly.
• What does your insurance actually cover — the pen/cap itself, the app, and the required CGM sensor? Coverage gaps between these three components are common.
• Are you someone who will consistently respond to alerts? Based on the Laurenzi et al. findings, the system’s real-world benefit appears tied closely to how promptly a user acts on what it tells them — worth an honest self-assessment before committing.

🎯 Who This Is Actually Right For

If you’re on multiple daily injections and finding it hard to track doses or catch missed ones, a dose-logging pen like the NovoPen line solves a real, specific problem with minimal added complexity.

If you’re already using a compatible CGM and want dosing support without moving to a full pump, a dose-recommending system like InPen or MiniMed Go is a reasonable next step — with the realistic expectation, based on the available evidence, that its benefit depends heavily on how consistently you engage with its alerts, not just on owning the device.

If you’re weighing this category against a full automated insulin delivery (closed-loop) pump system, that’s a conversation worth having directly with your endocrinology team, since the right choice depends on individual factors — lifestyle, insurance, comfort with wearable hardware — that a general comparison can’t settle for you.

❓ Frequently Asked Questions

What’s the difference between a smart insulin pen and an insulin pump?

A smart pen still requires you to manually administer each injection, with the “smart” component logging doses or recommending a dose based on glucose data. A pump delivers insulin continuously through an infusion set worn on the body. Smart pens generally cost less and require less hardware commitment, while pumps offer more automation.

Is InPen or Bigfoot Unity better?

They’re not directly comparable in a simple better/worse sense — InPen is a reusable pen requiring cartridge refills and works with Guardian Connect or Dexcom G6 CGMs, while Bigfoot Unity is a cap system that fits onto standard disposable pens and requires the FreeStyle Libre 2. The right choice depends heavily on which CGM you already use or have coverage for.

Do smart insulin pens actually improve blood sugar control?

The best available real-world evidence (a 2025 peer-reviewed study of 1,852 users) found that outcomes improved substantially specifically among users who responded promptly and consistently to the system’s alerts, rather than automatically for all users. The study was correlational, not a randomized trial, so it shows a strong association rather than definitive proof of cause and effect.

Are smart insulin pens covered by insurance?

Coverage varies by system, insurer, and plan, and typically involves separate coverage considerations for the pen/cap, the companion app, and the required CGM sensor. Checking with your specific insurer and diabetes care team is the only reliable way to confirm coverage for a given system.

📚 Sources & References

• Laurenzi, A., et al., “Insights into the effective use of the Smart MDI system: Data from the first 1852 type 1 diabetes users,” Diabetic Medicine, 2025, DOI: 10.1111/dme.70161
• PubMed, study listing and author disclosures
• T1D Exchange, “Connected Insulin Delivery Devices” (InPen and Bigfoot Unity technical specifications)
• DiaTribe, “Insulin Dosing Made Easier – Smart Pen Caps Cleared by FDA”
• Engadget, “FDA approves the first smart insulin pen cap to help with dosing”
• HCPLive, “FDA Clears MiniMed Go Smart MDI App for Adults and Children with T1D, T2D”
• Medtronic Newsroom, “First real-world data on newest Medtronic Smart MDI system shows users responding to actionable alerts experienced strongest outcomes”
• StockTitan, “Medtronic starts Europe launch of MiniMed Go Smart MDI”
• MedDeviceGuide, “Connected Autoinjectors and Smart Pens: Drug Delivery Pathways in 2026”
• Diabetotech, “Connected Insulin Pens and Smart Insulin Pen Systems: Promise, Limits, and What Actually Exists Today”
• American Diabetes Association Consumer Guide, “Smart Insulin Pens”

Verification notes: The Laurenzi et al. 2025 study was independently located on PubMed, PMC, and the publisher (Wiley) directly and reviewed for its actual findings and disclosed limitations, rather than relying solely on secondary summaries. Its correlational design and Medtronic-affiliated authorship are disclosed in the text above, consistent with this site’s standard practice for industry-funded or industry-affiliated research. Bigfoot Unity’s reduced marketing visibility following Abbott’s 2024 acquisition is drawn from independent industry analysis (Diabetotech) rather than an official company statement, and is presented as a reasonable question for prospective users to raise directly with the manufacturer, not a confirmed discontinuation.

💡 The Bottom Line

Smart insulin pens are a genuinely useful, evidence-backed middle tier between plain injections and full pump systems — not a hyped-up category chasing pump-level marketing without pump-level evidence. The FDA clearances here are real and specific, and the strongest available outcome study, while correlational and industry-affiliated, points to something legitimately actionable: consistent, prompt response to the system’s alerts appears to matter more than the technology alone. That’s a genuinely different, more honest picture than “smart pen equals better blood sugar automatically” — and worth knowing before you or a healthcare provider decides which tier of this category actually fits your day-to-day life.

[Internal link placeholder: link to your existing CGM/glucose monitor post here — anchor text suggestion: “how continuous glucose monitors and the data behind them actually work”]